From the ongoing @IMFmyeloma #ASH20 talk, we discussed the simplified frailty score generated from the FIRST clinical trial data: https://t.co/NuDLhrTkjK However, I want to call attention to Figure 1 with respect to patient-reported outcomes. #thread 1/
RT @EagleMyeloma: Frailty and minimal residual disease (#MRD) in #myeloma are both predictive of outcome - probably equally important. Gen…
RT @EagleMyeloma: Frailty and minimal residual disease (#MRD) in #myeloma are both predictive of outcome - probably equally important. Gen…
RT @EagleMyeloma: Frailty and minimal residual disease (#MRD) in #myeloma are both predictive of outcome - probably equally important. Gen…
Risk stratification in #MultipleMyeloma #mmsm
Frailty and minimal residual disease (#MRD) in #myeloma are both predictive of outcome - probably equally important. Generating risk-adapted clinical trials is the next step to use these tools. #mmsm https://t.co/YTVzYIvhJB
RT @smbenlazar: A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treate…
RT @smbenlazar: A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treate…
RT @smbenlazar: A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treate…
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial | #OncoAlert #geriheme #gerionc #mmsm https://t.co/aj0LNo0N92
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial https://t.co/ouHQDasop1 #clinicaltrials https://t.co/TdkXHHuLrK